CellaVision bone marrow aspirate application gets CE mark
February 2026—CellaVision’s bone marrow aspirate application has received the CE mark as a class C product under the European Union in vitro diagnostic regulation.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Volta Labs adds WGS apps to Callisto platform
February 2026—Volta Labs is expanding its Callisto sample preparation platform by adding seven validated whole genome sequencing DNA apps.
Illumina gets CMS reimbursement for TSO Comprehensive
February 2026—Illumina announced that reimbursement has been granted for its FDA-approved in vitro diagnostic TruSight Oncology Comprehensive test.
Vitestro launches new website, video of Aletta ARPD
February 2026—Vitestro has launched a new corporate website (vitestro.com) and released the first publicly available video of its Aletta Autonomous Robotic Phlebotomy Device performing a diagnostic blood draw.
AMA approves PLA code for RenaDx
February 2026—The American Medical Association has approved a new CPT proprietary laboratory analyses code for Personalized Medicine Care Diagnostics’ RenaDx, a comprehensive kidney genetics panel.
Fujirebio launches RUO pTau 217 CSF assay
February 2026—Fujirebio launched the Lumipulse G pTau 217 CSF assay for the fully automated Lumipulse G immunoassay analyzers.
Takara Bio updates its spatial biology product portfolio
February 2026—Takara Bio USA has updated its spatial biology product portfolio with a new class of spatial technology.
Diasorin gets clearance, waiver for fourplex panel
February 2026—Diasorin has received FDA 510(k) clearance and CLIA waiver for its first assay, a flu A/B, RSV, and COVID-19 panel, to be used on the Liaison Nes point-of-care molecular diagnostic platform.
CMS finalizes pricing determination for OncoReveal CDx
January 2026—The Centers for Medicare and Medicaid Services has finalized its pricing determination for Pillar Biosciences’ OncoReveal CDx.
NEB launches flu A integrated indexing primer module
January 2026—New England Biolabs released its NEBNext Flu A Integrated Indexing Primer Module, designed to streamline and scale the sequencing of influenza A virus from a range of species and sample types using Oxford Nanopore Technologies platforms.